Strategic Partnership With Changi General Hospital (CGH): Towards Advanced Healthcare
The Shimadzu-CGH Clinomics Centre (SC³), a partnership between Changi General Hospital (CGH) and Shimadzu, enables the diagnoses of salt-sensitive and curable forms of hypertension through a combination of liquid chromatography and mass spectrometry (LC-MS/MS) technology, a method that is rapidly gaining recognition for analyzing clinical samples with higher analytical specificity and sensitivity.
CGH has successfully started performing clinical tests through the SC³ for patients to identify those with primary aldosteronism, a common but lesser-known, curable form of hypertension, and individuals with salt-sensitive hypertension. Harnessing the technology of LC-MS/MS and powered by artificial intelligence, new clinical tests that accurately measure the hormones aldosterone and renin were launched in February 2023 to enhance patient outcomes locally and in the region. To date, CGH has conducted over 1,000 clinical tests in patients with hypertension.
This is particularly important in Singapore where hypertension is the major cause of heart disease and stroke. According to findings from the Ministry of Health’s National Population Health Survey 2022 and Health Promotion Board’s National Nutrition Survey 2022, high blood pressure, or hypertension, affects one in three adult Singaporeans, with the local prevalence of hypertension having almost doubled over the last decade.
With the testing at the SC³, specimens can be processed locally, reducing the turnaround times from several weeks to 3–5 days, thus better enabling more patients to be successfully tested, diagnosed by doctors, and treated with precise care.
For more, read here.